Search hospitals > Ohio > Cleveland
Cleveland Clinic Cancer Center/Fairview Hospital
Claim this profileCleveland, Ohio 44111
Global Leader in Parotid Gland Cancer
Global Leader in Ovarian Cancer
Conducts research for Relapse
Conducts research for Cervical Adenocarcinoma
Conducts research for Lung Cancer
283 reported clinical trials
34 medical researchers
Summary
Cleveland Clinic Cancer Center/Fairview Hospital is a medical facility located in Cleveland, Ohio. This center is recognized for care of Parotid Gland Cancer, Ovarian Cancer, Relapse, Cervical Adenocarcinoma, Lung Cancer and other specialties. Cleveland Clinic Cancer Center/Fairview Hospital is involved with conducting 283 clinical trials across 271 conditions. There are 34 research doctors associated with this hospital, such as Peter Rose, MD, David Peereboom, MD, Nathan A. Pennell, and Dale Shepard.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Ovarian Cancer
Global LeaderStage IV
Stage III
BRCA1 positive
Top PIs
Peter Rose, MDCleveland Clinic Foundation2 years of reported clinical research
Expert in Ovarian Cancer
Expert in Cervical Adenocarcinoma
25 reported clinical trials
50 drugs studied
David Peereboom, MDCleveland Clinic6 years of reported clinical research
Expert in Glioblastoma
Studies Brain Tumor
20 reported clinical trials
32 drugs studied
Nathan A. PennellCleveland Clinic Foundation3 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
19 reported clinical trials
29 drugs studied
Dale ShepardCleveland Clinic8 years of reported clinical research
Studies Cystic Tumor
Studies Cancer
15 reported clinical trials
39 drugs studied
Clinical Trials running at Cleveland Clinic Cancer Center/Fairview Hospital
Ovarian Cancer
Lung Cancer
Breast Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Parotid Gland Cancer
Breast cancer
Oropharyngeal Carcinoma
Relapse
Prostate Cancer
Olaparib +/- Bevacizumab
for Ovarian Cancer
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Targeted Therapy
for Solid Tumors
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
Surgical Procedures
for Reducing Ovarian Cancer Risk
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cleveland Clinic Cancer Center/Fairview Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.